Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.60.

AQST has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Aquestive Therapeutics in a research note on Thursday, September 10th.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $3.89 on Tuesday. The firm has a market cap of $488.23 million, a P/E ratio of -5.98 and a beta of 1.49. The stock’s 50-day moving average is $4.66 and its two-hundred day moving average is $4.20. Aquestive Therapeutics has a fifty-two week low of $2.93 and a fifty-two week high of $6.87.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. As a group, research analysts expect that Aquestive Therapeutics will post -0.50 EPS for the current year.

Insider Activity

In other Aquestive Therapeutics news, insider Sherry Korczynski sold 8,750 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the transaction, the insider owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the sale, the chief executive officer owned 627,317 shares of the company’s stock, valued at $2,647,277.74. The trade was a 3.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 58,750 shares of company stock valued at $271,675 over the last three months. 6.81% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bratton Capital Management L.P. bought a new stake in shares of Aquestive Therapeutics during the second quarter worth approximately $40,813,585. BlackRock Inc. acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth $33,569,000. Bank of America Corp DE acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth about $6,941,000. Blue Owl Capital Holdings LP acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $3,923,000. Finally, Wasatch Advisors LP raised its holdings in shares of Aquestive Therapeutics by 57.8% during the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock worth $5,765,000 after acquiring an additional 507,527 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.